Predicting the effect of sirolimus on disease activity in patients with systemic lupus erythematosus using machine learning

被引:4
作者
Wang, Dong-Dong [1 ]
Li, Ya-Feng [2 ]
Zhang, Cun [3 ]
He, Su-Mei [4 ]
Chen, Xiao [5 ]
机构
[1] Xuzhou Med Univ, Sch Pharm, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou, Jiangsu, Peoples R China
[2] Feng Xian Peoples Hosp, Dept Pharm, Xuzhou, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Dept Pharm, Xuzhou Oriental Hosp, Xuzhou, Jiangsu, Peoples R China
[4] Nanjing Med Univ, Suzhou Sci & Technol Town Hosp, Gusu Sch, Dept Pharm, Suzhou 215153, Jiangsu, Peoples R China
[5] Xuzhou Med Univ, Sch Nursing, Xuzhou 221004, Jiangsu, Peoples R China
关键词
disease activity; machine learning; predicting; sirolimus; systemic lupus erythematosus; ACTIVITY INDEX; CANCER; MORTALITY; SAFETY;
D O I
10.1111/jcpt.13778
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What Is Known and Objectives The present study aimed to predict the effect of sirolimus on disease activity in patients with systemic lupus erythematosus (SLE) using machine learning and to recommend appropriate sirolimus dosage regimen for patients with SLE. Methods The E-max model was selected for machine learning, where the evaluation indicator was the change rate of systemic lupus erythematosus disease activity index from baseline value. Results A total 103 patients with SLE were included for modelling, where the E-max, ET50 were -53.9%, 1.53 months in the final model respectively, and the evaluation of the final model was good. Further simulation found that the follow-up time to achieve 25%, 50%, 75% and 80% (plateau) E-max of sirolimus effecting on disease activity in patients with SLE were 0.51, 1.53, 4.59 and 6.12 months, respectively. In addition, the sirolimus dosage was flexible and adjusted according to drug concentration, where the intersection of sirolimus concentration range included in this study was about 8-10 ng/ml. What Is New and Conclusions This study was the first time to predict the effect of sirolimus on disease activity in patients with SLE and in order to achieve better therapeutic effect maintaining a concentration of 8-10 ng/ml sirolimus for at least 6.12 months was necessary.
引用
收藏
页码:1845 / 1850
页数:6
相关论文
共 35 条
[1]   Big Data and Machine Learning in Health Care [J].
Beam, Andrew L. ;
Kohane, Isaac S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (13) :1317-1318
[2]   Mortality in systemic lupus erythematosus [J].
Bernatsky, S. ;
Boivin, J. -F. ;
Joseph, L. ;
Manzi, S. ;
Ginzler, E. ;
Gladman, D. D. ;
Urowitz, M. ;
Fortin, P. R. ;
Petri, M. ;
Barr, S. ;
Gordon, C. ;
Bae, S. -C. ;
Isenberg, D. ;
Zoma, A. ;
Aranow, C. ;
Dooley, M. -A. ;
Nived, O. ;
Sturfelt, G. ;
Steinsson, K. ;
Alarcon, G. ;
Senecal, J. -L. ;
Zummer, M. ;
Hanly, J. ;
Ensworth, S. ;
Pope, J. ;
Edworthy, S. ;
Rahman, A. ;
Sibley, J. ;
El-Gabalawy, H. ;
McCarthy, T. ;
Pierre, Y. St. ;
Clarke, A. ;
Ramsey-Goldman, R. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2550-2557
[3]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[4]   Explainable Machine Learning for Early Assessment of COVID-19 Risk Prediction in Emergency Departments [J].
Casiraghi, Elena ;
Malchiodi, Dario ;
Trucco, Gabriella ;
Frasca, Marco ;
Cappelletti, Luca ;
Fontana, Tommaso ;
Esposito, Alessandro Andrea ;
Avola, Emanuele ;
Jachetti, Alessandro ;
Reese, Justin ;
Rizzi, Alessandro ;
Robinson, Peter N. ;
Valentini, Giorgio .
IEEE ACCESS, 2020, 8 (08) :196299-196325
[5]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[6]   Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors [J].
Chaix, Marie-A ;
Parmar, Neha ;
Kinnear, Caroline ;
Lafreniere-Roula, Myriam ;
Akinrinade, Oyediran ;
Yao, Roderick ;
Miron, Anastasia ;
Lam, Emily ;
Meng, Guoliang ;
Christie, Anne ;
Manickaraj, Ashok Kumar ;
Marjerrison, Stacey ;
Dillenburg, Rejane ;
Bassal, Mylene ;
Lougheed, Jane ;
Zelcer, Shayna ;
Rosenberg, Herschel ;
Hodgson, David ;
Sender, Leonard ;
Kantor, Paul ;
Manlhiot, Cedric ;
Ellis, James ;
Mertens, Luc ;
Nathan, Paul C. ;
Mital, Seema .
JACC: CARDIOONCOLOGY, 2020, 2 (05) :690-706
[7]   The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety [J].
Chen, Xiaoli ;
Sun, Hengrui ;
Cassady, Kaniel ;
Yang, Shijie ;
Chen, Ting ;
Wang, Li ;
Yan, Hongju ;
Zhang, Xi ;
Feng, Yimei .
FRONTIERS IN ONCOLOGY, 2021, 11
[8]   Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus [J].
Eriksson, Per ;
Wallin, Philip ;
Sjowall, Christopher .
FRONTIERS IN PHARMACOLOGY, 2019, 10
[9]   2019 update of the EULAR recommendations for the management of systemic lupus erythematosus [J].
Fanouriakis, Antonis ;
Kostopoulou, Myrto ;
Alunno, Alessia ;
Aringer, Martin ;
Bajema, Ingeborg ;
Boletis, John N. ;
Cervera, Ricard ;
Doria, Andrea ;
Gordon, Caroline ;
Govoni, Marcello ;
Houssiau, Frederic ;
Jayne, David ;
Kouloumas, Marios ;
Kuhn, Annegret ;
Larsen, Janni L. ;
Lerstrom, Kirsten ;
Moroni, Gabriella ;
Mosca, Marta ;
Schneider, Matthias ;
Smolen, Josef S. ;
Svenungsson, Elisabet ;
Tesar, Vladimir ;
Tincani, Angela ;
Troldborg, Anne ;
van Vollenhoven, Ronald ;
Wenzel, Joerg ;
Bertsias, George ;
Boumpas, Dimitrios T. .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (06) :736-745
[10]   Systemic lupus erythematosus: Diagnosis and clinical management [J].
Fava, Andrea ;
Petri, Michelle .
JOURNAL OF AUTOIMMUNITY, 2019, 96 :1-13